{
    "clinical_study": {
        "@rank": "83951", 
        "arm_group": [
            {
                "arm_group_label": "Electronic detailed information", 
                "arm_group_type": "Experimental", 
                "description": "Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease."
            }, 
            {
                "arm_group_label": "NAFLD Score", 
                "arm_group_type": "Experimental", 
                "description": "Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by NAFLD score."
            }, 
            {
                "arm_group_label": "NAFLD Score plus Transient elastography", 
                "arm_group_type": "Experimental", 
                "description": "Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by NAFLD score and transient elastography."
            }, 
            {
                "arm_group_label": "Transient elastography", 
                "arm_group_type": "Experimental", 
                "description": "Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by transient elastography."
            }, 
            {
                "arm_group_label": "Standard of care", 
                "arm_group_type": "No Intervention", 
                "description": "Standard of care for patients with diagnosis of fatty liver by ultrasound."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this randomized clinical trial is to evaluate the utility of noninvasive\n      markers for the detection of advanced fibrosis in patients newly diagnosed with\n      Non-alcoholic Fatty Liver Disease  (NAFLD) by ultrasound.\n\n      The primary objective is to determine the effectiveness of noninvasive markers for detect of\n      advanced fibrosis in patients with diagnosis of fatty liver disease.\n\n      The secondary objectives are:\n\n        -  To determine the increase in health care with the specialist (gastroenterologist or\n           endocrinologist).\n\n        -  To determine which noninvasive evaluation strategy favors any treatment of fatty liver\n           disease."
        }, 
        "brief_title": "Non Invasive Assessment of Liver Fibrosis in Fatty Liver Disease", 
        "condition": "Non Alcoholic Fatty Liver Disease", 
        "condition_browse": {
            "mesh_term": [
                "Fatty Liver", 
                "Fibrosis", 
                "Liver Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with BMI \u2265 27 Kg/m2 and any stage of non alcoholic fatty liver, diagnosed by\n             ultrasound.\n\n        Exclusion Criteria:\n\n          -  Patients with other liver disease.\n\n          -  Patients under treatment with tamoxifen, methotrexate, amiodarone, diltiazem or other\n             drugs able to induce fatty liver.\n\n          -  Patients with alcohol consumption greater than 140 gr. per week\n\n          -  Patients who have received blood transfusion before 1990"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "69 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "594", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01874249", 
            "org_study_id": "FAFLD"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Electronic detailed information", 
                    "NAFLD Score", 
                    "NAFLD Score plus Transient elastography", 
                    "Transient elastography"
                ], 
                "description": "Electronic detailed information about non alcoholic fatty liver disease.", 
                "intervention_name": "Electronic detailed information", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "NAFLD Score", 
                    "NAFLD Score plus Transient elastography"
                ], 
                "description": "diagnosis of advanced fibrosis by NAFLD score, calculated according to Hepatology 2007;45(4):846-854", 
                "intervention_name": "NAFLD Score", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "NAFLD Score plus Transient elastography", 
                    "Transient elastography"
                ], 
                "description": "Transient elastography values greater than 8 kPa", 
                "intervention_name": "Transient elastography", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hepatic fibrosis", 
            "Steatosis", 
            "Noninvasive markers."
        ], 
        "lastchanged_date": "June 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Mexico City", 
                    "country": "Mexico", 
                    "state": "DF", 
                    "zip": "14050"
                }, 
                "name": "Medica Sur Clinic & Foundation"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "5", 
        "official_title": "Randomized Clinical Trial to Detect Advanced Fibrosis by Non-invasive Methods in Subjects With Non-alcoholic Fatty Liver Disease", 
        "overall_contact": {
            "email": "khavez@gmail.com", 
            "last_name": "Norberto C Ch\u00e1vez-Tapia, MD", 
            "phone": "5554246850"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Mexico: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evidence of advanced fibrosis, diagnosed by transient elastography (greater than 8 kPa), NAFLD Score above 0.675, liver biopsy or any other non-invasive marker of liver fibrosis.", 
            "measure": "Advanced Fibrosis by any diagnostic modality", 
            "safety_issue": "No", 
            "time_frame": "One year after the diagnosis of steatosis."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01874249"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur", 
            "investigator_full_name": "Norberto Carlos Chavez Taia", 
            "investigator_title": "Norberto Carlos Chavez-Tapia", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Through telephone follow-up, investigate if the patient attends to gastroenterologist or endocrinologist for examination, diagnostic confirmation or any treatment.", 
            "measure": "Specialized care", 
            "safety_issue": "No", 
            "time_frame": "One year  after the diagnosis of steatosis."
        }, 
        "source": "Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}